Importantly, ICI response is strongly associated with tumor PD-L1 levels [33] suggesting that glottic cancers may be more favorable target for immunotherapy than supraglottic cancers; however, this will need to be confirmed in the context of prospective trials. The gene discussed is CD274; the disease is neoplasm.